Literature DB >> 18455276

Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice.

Joseph P Shott1, Shannon M McGrath, Maria Grazia Pau, Jerome H V Custers, Olga Ophorst, Marie-Ange Demoitié, Marie-Claude Dubois, Jack Komisar, Michelle Cobb, Kent E Kester, Patrice Dubois, Joe Cohen, Jaap Goudsmit, D Gray Heppner, V Ann Stewart.   

Abstract

Falciparum malaria vaccine candidates have been developed using recombinant, replication-deficient serotype 5 and 35 adenoviruses (Ad5, Ad35) encoding the Plasmodium falciparum circumsporozoite surface protein (CSP) (Ad5.CS, Ad35.CS) (Crucell Holland BV, Leiden, The Netherlands). To evaluate the immunogenicity of these constructs, BALB/cJ mice were immunized twice with either Ad5.CS, Ad35.CS, empty Ad5-vector (eAd5), empty Ad35 vector (eAd35), or saline. Another group received the CSP-based RTS,S malaria vaccine formulated in the proprietary Adjuvant System AS01B (GlaxoSmithKline Biologicals, Rixensart, Belgium). Here we report that Ad5.CS, Ad35.CS, and RTS,S/AS01B, elicited both cellular and serologic CSP antigen-specific responses in mice. These adenoviral vectors induce strong malaria-specific immunity and warrant further evaluation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18455276     DOI: 10.1016/j.vaccine.2008.03.080

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines.

Authors:  Stefan Kostense; Bregje Mommaas; Jenny Hendriks; Mariëlle Verhoeven; Mariska Ter Haak; Felicia Tirion; Edison Wiesken; Maria Grazia Pau; Katarina Radosevic; Jaap Goudsmit
Journal:  Clin Vaccine Immunol       Date:  2011-03-16

2.  Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice.

Authors:  Sergey S Seregin; Yasser A Aldhamen; David P W Rastall; Sarah Godbehere; Andrea Amalfitano
Journal:  Vaccine       Date:  2011-12-23       Impact factor: 3.641

3.  A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.

Authors:  Jairo A Fonseca; Jessica N McCaffery; Elena Kashentseva; Balwan Singh; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  Vaccine       Date:  2017-05-05       Impact factor: 3.641

4.  Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.

Authors:  C Buddy Creech; Cornelia L Dekker; Dora Ho; Shanda Phillips; Sally Mackey; Cristina Murray-Krezan; Maria Grazia Pau; Jenny Hendriks; Valerie Brown; Leonard G Dally; Isabella Versteege; Kathryn M Edwards
Journal:  Hum Vaccin Immunother       Date:  2013-08-17       Impact factor: 3.452

5.  Viral vectors for vaccine applications.

Authors:  Youngjoo Choi; Jun Chang
Journal:  Clin Exp Vaccine Res       Date:  2013-07-03

6.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

7.  A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.

Authors:  Monica Cabrera-Mora; Jairo Andres Fonseca; Balwan Singh; Chunxia Zhao; Natalia Makarova; Igor Dmitriev; David T Curiel; Jerry Blackwell; Alberto Moreno
Journal:  J Immunol       Date:  2016-08-29       Impact factor: 5.422

Review 8.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

9.  Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA.

Authors:  B Ferraro; K T Talbott; A Balakrishnan; N Cisper; M P Morrow; N A Hutnick; D J Myles; D J Shedlock; N Obeng-Adjei; J Yan; A K K Kayatani; N Richie; W Cabrera; R Shiver; A S Khan; A S Brown; M Yang; U Wille-Reece; A J Birkett; N Y Sardesai; D B Weiner
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

10.  Epidemiology of malaria in an area prepared for clinical trials in Korogwe, north-eastern Tanzania.

Authors:  Bruno P Mmbando; Method D Segeja; Hamisi A Msangeni; Samwel H Sembuche; Deus S Ishengoma; Misago D Seth; Filbert Francis; Acleus S Rutta; Mathias L Kamugisha; Martha M Lemnge
Journal:  Malar J       Date:  2009-07-18       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.